ストックスクリーナーアプリを入手
17.60
6.47%
1.07
アフターアワーズ：
17.60
Liquidia Corp (LQDA) 最新ニュース
Liquidia at Jefferies Conference: Strategic Moves in PAH Market - Investing.com
BTIG Raises Liquidia Price Target Following YUTREPIA Approval - Insider Monkey
Stocks To Watch: Liquidia Sees Relative Strength Rating Jump To 93 - inkl
Judge Denies UTC Bid To Block Liquidia's Lung Drug - Law360
BTIG raises Liquidia stock price target following FDA approval By Investing.com - Investing.com South Africa
Raymond James maintains strong buy on Liquidia stock following court ruling - Investing.com India
BTIG raises Liquidia stock price target following FDA approval - Investing.com
Liquidia Beats UTC Bid to Block Launch of Lung Drug Yutrepia - Bloomberg Law News
Liquidia stock rises following YUTREPIA shipment news - Investing.com
Needham raises Liquidia Technologies stock price target after court ruling By Investing.com - Investing.com India
Liquidia (LQDA) Gets Price Target Boost from Needham | LQDA Stock News - GuruFocus
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension - marketscreener.com
Liquidia starts commercial shipment of FDA-approved YUTREPIA By Investing.com - Investing.com India
Liquidia (LQDA) Begins Commercial Launch of YUTREPIA Following L - GuruFocus
Liquidia starts commercial shipment of FDA-approved YUTREPIA - Investing.com
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - The Manila Times
BTIG reaffirms buy rating for Liquidia stock amid legal developments By Investing.com - Investing.com South Africa
Liquidia (LQDA) Stock Price Target Raised by Analyst | LQDA Stoc - GuruFocus
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
BTIG reaffirms buy rating for Liquidia stock amid legal developments - Investing.com
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Revista ADVFN
Liquidia Told to Swap Two Defenses Ahead of Trial on UTC Patent - Bloomberg Law News
Wells Fargo lifts Liquidia stock price target to $23 from $20 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod By Investing.com - Investing.com South Africa
Scotiabank Raises Price Target for Liquidia (LQDA) to $37.00 | LQDA Stock News - GuruFocus
These Analysts Boost Their Forecasts On Liquidia - Benzinga
Scotiabank Increases Price Target for Liquidia (LQDA) After Yutrepia Approval | LQDA Stock News - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analy - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analyst | LQDA Stock News - GuruFocus
Liquidia Technologies stock target raised to $33 at Raymond James - Investing.com
Breaking Down Liquidia: 12 Analysts Share Their Views - Benzinga
Liquidia (LQDA) Price Target Raised to $35 by HC Wainwright | LQ - GuruFocus
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQ - GuruFocus
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch By Investing.com - Investing.com South Africa
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQDA Stock News - GuruFocus
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Liquidia (LQDA) Gains FDA Approval, Price Target Raised to $23 | - GuruFocus
Liquidia (LQDA) Gains FDA Approval, Price Target Raised to $23 | LQDA Stock News - GuruFocus
Needham Reiterates Buy Rating on LQDA with a Price Target of $25 - GuruFocus
Wells Fargo lifts Liquidia stock price target to $23 from $20 - Investing.com
Needham Reiterates Buy Rating on LQDA with a Price Target of $25.00 | LQDA Stock News - GuruFocus
BTIG raises Liquidia stock price target to $37, maintains buy - Investing.com
Liquidia (LQDA) Sees Price Target Boost After FDA Approval | LQD - GuruFocus
Liquidia (LQDA) Sees Price Target Boost After FDA Approval | LQDA Stock News - GuruFocus
Jefferies raises Liquidia Technologies stock target to $31 - Investing.com
Jefferies Boosts Liquidia (LQDA) Price Target After FDA Approval - GuruFocus
Jefferies Boosts Liquidia (LQDA) Price Target After FDA Approval | LQDA Stock News - GuruFocus
Jefferies Lifts Liquidia Technologies' Price Target to $31 From $27, Buy Rating Kept - marketscreener.com
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Transcript : Liquidia CorporationSpecial Call - marketscreener.com
BTIG maintains Liquidia stock Buy rating, $29 target - Investing.com
Raymond James maintains Strong Buy on Liquidia stock, $29 target - Investing.com
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod - MSN
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod By Stocktwits - Investing.com India
Liquidia (LQDA) Price Target Boosted to $25 by BofA | LQDA Stock News - GuruFocus
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus
Liquidia (LQDA) Trading Resumes After Brief Halt | LQDA Stock Ne - GuruFocus
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension - marketscreener.com
Liquidia (LQDA) Trading Resumes After Brief Halt | LQDA Stock News - GuruFocus
FDA Greenlights Liquidia's (LQDA) Yutrepia for Pulmonary Hyperte - GuruFocus
U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - The Manila Times
Trading Halted for Liquidia (LQDA) as Anticipated News Awaits | - GuruFocus
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - Yahoo Finance
Trading Halted for Liquidia (LQDA) as Anticipated News Awaits | LQDA Stock News - GuruFocus
Scotiabank maintains Liquidia stock with $36 target - Investing.com
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):